Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women

被引:24
|
作者
Tian, Yaping [1 ]
Wang, Chuanxin [2 ]
Cheng, Liming [3 ]
Zhang, Aimin [4 ]
Liu, Wen [5 ]
Guo, Lin [6 ]
Ye, Huiming [7 ]
Huang, Yanchun [8 ]
Chen, Jing [9 ]
Wen, Xinyu [1 ]
Xing, Yuelei [1 ]
Zheng, Guixi [2 ]
Sun, Ziyong [3 ]
Li, Huijun [3 ]
Zhang, Peng [4 ]
Liu, Wanli [5 ]
Chen, Ying [6 ]
Zhang, Zhongying [7 ]
Xu, Yi [8 ]
Huo, Yishan [8 ]
Ou, Qishui [9 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Clin Biochem, Beijing 100853, Peoples R China
[2] Shandong Univ, Dept Clin Lab, Qilu Hosp, Jinan 250012, Shandong, Peoples R China
[3] Tongji Med Coll HUST, Tongji Hosp, Dept Lab Med, Wuhan 430030, Hubei Province, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Dept Clin Lab, Tianjin 300060, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Dept Clin Lab, Guangzhou 510060, Guangdong, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Dept Clin Lab, Shanghai 200032, Peoples R China
[7] Xiamen Univ, Zhongshan Hosp, Dept Clin Lab, Xiamen 361004, Fujian Province, Peoples R China
[8] Xinjiang Med Univ, Tumor Hosp, Clin Lab Ctr, Urumqi 830011, Xinjiang Provin, Peoples R China
[9] Fujian Med Univ, Affiliated Hosp 1, Dept Lab Med, Fuzhou 350005, Fujian Province, Peoples R China
基金
中国国家自然科学基金;
关键词
Human epididymis protein 4; Epithelial ovarian cancer; Pelvic masses; OVARIAN-CANCER DIAGNOSIS; CARBOHYDRATE ANTIGEN 125; OUR-EXPERIENCE; CA125; ALGORITHM; CARCINOMA; LAPAROSCOPY; BIOMARKERS; MANAGEMENT; MULTIPLE;
D O I
10.1186/s13048-015-0201-z
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: To determine reference intervals for serum levels of human epididymis protein 4 (HE4) in Chinese women. Methods: In this multicenter (n = 9) study, 618 healthy women, 767 patients with non-malignant diseases, and 951 patients with malignant tumors were enrolled. Serum levels of HE4 were measured in all patients using electrochemiluminescence immunoassays. The influence of age, menopause, malignancy status and other characteristics on the levels of HE4 was evaluated using univariate and multivariate analyses. Confidence intervals (2.5-97.5 %) were determined in different populations. Results: There were significant differences in HE4 levels among groups with different ages, menopause or malignancy status. Higher levels of HE4 were detected in elder compared to younger, post- compare to pre-menopause and malignant compared to benign subjects. Multivariate analysis showed that menopause and malignancy status, as well as smoking and pelvic masses were independent factors involved in serum HE4 levels. In pre-menopause stage, the reference ranges of HE4 level were 29.30-68.79, 28.12-1284.83 and 34.75-981.91 pmol/L in healthy, benign and malignant populations, respectively. In post-menopause stage, the reference ranges are 35.96-114.43, 39.11-2208.70 and 39.40-1678.13 pmol/L for those populations. Conclusions: The present study has established the reference intervals of HE4 levels in pre- and post-menopause populations with different malignancy status.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [1] Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women
    Yaping Tian
    Chuanxin Wang
    Liming Cheng
    Aimin Zhang
    Wen Liu
    Lin Guo
    Huiming Ye
    Yanchun Huang
    Jing Chen
    Xinyu Wen
    Yuelei Xing
    Guixi Zheng
    Ziyong Sun
    Huijun Li
    Peng Zhang
    Wanli Liu
    Ying Chen
    Zhongying Zhang
    Yi Xu
    Yishan Huo
    Qishui Ou
    Journal of Ovarian Research, 8
  • [2] Serum human epididymis protein 4 (HE4) levels in colorectal cancer patients.
    Kemal, Yasemin
    Gonullu, Guzin
    Bedir, Addulkerim
    Tomak, Leman
    Derebey, Murat
    Erdem, Dilek
    Gor, Ufuk
    Yucel, Idris
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Should we apply different reference ranges for human epididymis protein 4 (HE4) in pregnant women?
    Koleva, V.
    Shefket, S.
    CLINICA CHIMICA ACTA, 2024, 558 : 80 - 80
  • [4] The Utility of Serum Human Epididymis Protein 4 (HE4) in Patients With a Pelvic Mass
    Montagnana, Martina
    Lippi, Giuseppe
    Ruzzenente, Orazio
    Bresciani, Valentina
    Danese, Elisa
    Scevarolli, Silvia
    Salvagno, Gian Luca
    Giudici, Silvia
    Franchi, Massimo
    Guidi, Gian Cesare
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2009, 23 (05) : 331 - 335
  • [5] Comparison of Serum Human Epididymis Protein 4 (HE4) Levels in Breast Cancer Patients and Healthy Individuals
    Zahra Honarvar
    Behjat Kalantari Khandani
    Mohaddeseh Nazari
    Fatemeh Karami Robati
    Indian Journal of Gynecologic Oncology, 2021, 19
  • [6] Human epididymis secretory protein 4 in serum (HE4) as a marker of ovarian cancer
    Qu, K. Z.
    Li, H.
    Whitmire, R.
    Sferruzza, A.
    Bender, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Comparison of Serum Human Epididymis Protein 4 (HE4) Levels in Breast Cancer Patients and Healthy Individuals
    Honarvar, Zahra
    Khandani, Behjat Kalantari
    Nazari, Mohaddeseh
    Robati, Fatemeh Karami
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [8] Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer
    Nagy, Bela, Jr.
    Bhattoa, Harjit Pal
    Steiber, Zoltan
    Csoban, Maria
    Szilasi, Maria
    Mehes, Gabor
    Mueller, Monika
    Lazar, Jozsef
    Kappelmayer, Janos
    Antal-Szalmas, Peter
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (11) : 1639 - 1648
  • [9] A clinical study of serum human epididymis protein 4 (HE4) in the diagnosis of pancreatic cancer
    Liu, Weiqi
    Liu, Weiling
    Lin, Keng
    Liu, Yuhua
    Hu, He
    Yang, Lina
    INDIAN JOURNAL OF CANCER, 2022, 59 (02) : 223 - 229
  • [10] Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma
    Chang, Xiaohong
    Ye, Xue
    Dong, Li
    Cheng, Hongyan
    Cheng, Yexia
    Zhu, Lirong
    Liao, Qinping
    Zhao, Yang
    Tian, Li
    Fu, Tianyun
    Chen, Jun
    Cui, Heng
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (05) : 852 - 858